© 2002 by Oxford University Press
Journal of the National Cancer Institute, Vol. 94, No. 16, 1197-1203,
August 21, 2002
© 2002 Oxford University Press
REVIEW |
Clinical Utility of Proton Magnetic Resonance Spectroscopy in Characterizing Breast Lesions
Affiliation of authors: R. Katz-Brull, R. E. Lenkinski (Department of Radiology), P. T. Lavin (Department of Surgery), Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA.
Correspondence to: Robert E. Lenkinski, Ph.D., Center for Advanced Imaging, W/CC-090, Beth Israel Deaconess Medical Center, One Deaconess Rd., Boston, MA 02215 (e-mail: rlenkins{at}caregroup.harvard.edu).
Proton magnetic resonance spectroscopy (1H MRS) of the breast has been proposed as an adjunct to the magnetic resonance imaging (MRI) examination to improve the specificity of distinguishing malignant breast tumors from benign breast tumors. In this review, we carry out a pooled analysis of the clinical breast 1H MRS studies undertaken to date to determine the factors that influence the diagnostic performance of this method. In total, five studies of breast 1H MRS from four independent centers around the world have been published to date. Altogether, 153 tumors were examined, 100 of which were confirmed histologically to be malignant and 53 of which were benign. The lesions presenting a detectable composite choline signal in their corresponding 1H MR spectra were diagnosed as malignant, whereas the lesions with no choline signal were diagnosed as benign. The sensitivity and specificity of breast 1H MRS for detecting breast cancer were 83% (95% confidence interval [CI] = 73% to 89%) and 85% (95% CI = 71% to 93%), respectively, and both values could be as high as 92% after technical exclusions. In a subgroup of 20 young women, the sensitivity and the specificity of the method approached 100%. The factors limiting the sensitivity of the examination were mainly technical. The use of the composite choline signal as a marker for malignancy in breast 1H MRS is a robust method with highly reliable interpretation, because it is based on the appearance of a single peak. The method is likely to provide even better results with technologic advances in breast MRS that lead to the improved detection of the composite choline signal.
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  R. L. Birdwell, C. E. Mountford, and J. D. Iglehart Molecular Imaging of the Breast Am. J. Roentgenol., August 1, 2009; 193(2): 367 - 376. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
F. Sardanelli, A. Fausto, G. Di Leo, R. de Nijs, M. Vorbuchner, and F. Podo In Vivo Proton MR Spectroscopy of the Breast Using the Total Choline Peak Integral as a Marker of Malignancy Am. J. Roentgenol., June 1, 2009; 192(6): 1608 - 1617. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H.-M. Baek, J.-H. Chen, K. Nie, H. J. Yu, S. Bahri, R. S. Mehta, O. Nalcioglu, and M.-Y. Su Predicting Pathologic Response to Neoadjuvant Chemotherapy in Breast Cancer by Using MR Imaging and Quantitative 1H MR Spectroscopy Radiology, June 1, 2009; 251(3): 653 - 662. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. Bartella and W. Huang Proton (1H) MR Spectroscopy of the Breast RadioGraphics, October 1, 2007; 27(suppl_1): S241 - S252. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. Stanwell and C. Mountford In Vivo Proton MR Spectroscopy of the Breast RadioGraphics, October 1, 2007; 27(suppl_1): S253 - S266. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. C. Genson, C. E. Blane, M. A. Helvie, S. A. Waits, and T. L. Chenevert Effects on Breast MRI of Artifacts Caused by Metallic Tissue Marker Clips Am. J. Roentgenol., February 1, 2007; 188(2): 372 - 376. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. G. Sorensen Magnetic Resonance As a Cancer Imaging Biomarker J. Clin. Oncol., July 10, 2006; 24(20): 3274 - 3281. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. Workman, E. O. Aboagye, Y.-L. Chung, J. R. Griffiths, R. Hart, M. O. Leach, R. J. Maxwell, P. M. J. McSheehy, P. M. Price, and J. Zweit Minimally invasive pharmacokinetic and pharmacodynamic technologies in hypothesis-testing clinical trials of innovative therapies. J Natl Cancer Inst, May 3, 2006; 98(9): 580 - 598. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 N. Shah, A. Sattar, M. Benanti, S. Hollander, and L. Cheuck Magnetic Resonance Spectroscopy as an Imaging Tool for Cancer: A Review of the Literature J Am Osteopath Assoc, January 1, 2006; 106(1): 23 - 27. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. Glunde, V. Raman, N. Mori, and Z. M. Bhujwalla RNA Interference-Mediated Choline Kinase Suppression in Breast Cancer Cells Induces Differentiation and Reduces Proliferation Cancer Res., December 1, 2005; 65(23): 11034 - 11043. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. Iorio, D. Mezzanzanica, P. Alberti, F. Spadaro, C. Ramoni, S. D'Ascenzo, D. Millimaggi, A. Pavan, V. Dolo, S. Canevari, et al. Alterations of Choline Phospholipid Metabolism in Ovarian Tumor Progression Cancer Res., October 15, 2005; 65(20): 9369 - 9376. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Meisamy, P. J. Bolan, E. H. Baker, M. G. Pollema, C. T. Le, F. Kelcz, M. C. Lechner, B. A. Luikens, R. A. Carlson, K. R. Brandt, et al. Adding in Vivo Quantitative 1H MR Spectroscopy to Improve Diagnostic Accuracy of Breast MR Imaging: Preliminary Results of Observer Performance Study at 4.0 T Radiology, August 1, 2005; 236(2): 465 - 475. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. Katz-Brull, N. M. Rofsky, M. M. Morrin, I. Pedrosa, D. J. George, M. D. Michaelson, R. P. Marquis, M. Maril, C. Noguera, and R. E. Lenkinski Decreases in free cholesterol and fatty acid unsaturation in renal cell carcinoma demonstrated by breath-hold magnetic resonance spectroscopy Am J Physiol Renal Physiol, April 1, 2005; 288(4): F637 - F641. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Meisamy, P. J. Bolan, E. H. Baker, R. L. Bliss, E. Gulbahce, L. I. Everson, M. T. Nelson, T. H. Emory, T. M. Tuttle, D. Yee, et al. Neoadjuvant Chemotherapy of Locally Advanced Breast Cancer: Predicting Response with in Vivo 1H MR Spectroscopy--A Pilot Study at 4 T Radiology, November 1, 2004; 233(2): 424 - 431. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
F. Sardanelli, G. M. Giuseppetti, P. Panizza, M. Bazzocchi, A. Fausto, G. Simonetti, V. Lattanzio, and A. Del Maschio Sensitivity of MRI Versus Mammography for Detecting Foci of Multifocal, Multicentric Breast Cancer in Fatty and Dense Breasts Using the Whole-Breast Pathologic Examination as a Gold Standard Am. J. Roentgenol., October 1, 2004; 183(4): 1149 - 1157. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. Glunde, C. Jie, and Z. M. Bhujwalla Molecular Causes of the Aberrant Choline Phospholipid Metabolism in Breast Cancer Cancer Res., June 15, 2004; 64(12): 4270 - 4276. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. D. Yeh Characterization of Breast Lesions with Proton MR Spectroscopy Am. J. Roentgenol., November 1, 2003; 181(5): 1273 - 1274. [Full Text] [PDF]
|
|
|
|
 |
|
 M. G. Harisinghani, J. Barentsz, P. F. Hahn, W. M. Deserno, S. Tabatabaei, C. H. van de Kaa, J. de la Rosette, and R. Weissleder Noninvasive Detection of Clinically Occult Lymph-Node Metastases in Prostate Cancer N. Engl. J. Med., June 19, 2003; 348(25): 2491 - 2499. [Abstract] [Full Text] [PDF]
|
|